RPT-Targeted drugs in focus ahead of cancer meeting

gene known as ALK. [ID:nN18299647] Only about 4 percent of the lung cancer population is ALK-positive and Abbott Laboratories (ABT.N Roche's Ventana diagnostics unit has a test that can weed out the low Met patients who would not be helped by MetMAB. On...